December 21, 2022

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 

Re:

HTG Molecular Diagnostics, Inc.

Registration Statement on Form S-1 (Registration No. 333-268681) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursuant to the registration statement on Form S-1 (333-268681) (the “Registration Statement”), hereby concurs in the request by HTG Molecular Diagnostics, Inc. (the “Company”) that the effective date of the above-referenced registration statement be accelerated to 1:00 P.M. (Eastern Time), or as soon as practicable thereafter, on December 21, 2022, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that the Registration Statement be declared effective, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

 

430 Park Avenue | New York, NY 10022 | 212.356.0500 | www.hcwco.com

Member: FINRA/SIPC